PanGenomic Health Signs Letter of Intent with Ayla BioScience

Executive Summary

• PanGenomic Health entered into a non‑binding LOI with Ayla BioScience to negotiate an exclusive distribution agreement for Zeotech products in Canada.
• The LOI includes a proposed equity investment by PanGenomic of up to C$150,000 in Ayla BioScience, payable in cash and PanGenomic shares.
• The transaction remains subject to due‑diligence, definitive agreements, closing conditions and any required approval from the Canadian Securities Exchange.

Key Details

• Parties: PanGenomic Health Inc. (CSE: NARA) and Ayla BioScience, Inc. (Delaware corporation).
• Distribution Agreement: Exclusive right for PanGenomic to market and distribute “Zeotech Products” in Canada for a minimum term of two years as part of its personalized‑medicine platform.
• Equity Investment: Up to C$150,000 purchase price; payment to be made in a combination of cash and PanGenomic Health shares.
• Technology & Brands: Ayla BioScience utilizes proprietary ZeoDry™ dehydration technology and markets products under the ZeoMycel™ (functional mushroom) and Zeophytoz™ (botanical extracts) brands.
• Conditions to Closing: Execution of definitive documentation, satisfaction of any closing conditions, and approval by the Canadian Securities Exchange if required. No change‑of‑control is expected from the share issuance.
• Forward‑Looking Statements: The release contains typical forward‑looking language; completion of the transaction is not guaranteed.

Notable Quotes

(No direct quotes were provided in the release.)